Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 212 pages

Showing 151 - 200


prostate cancer

Final 8-Year Analysis of Intergroup Trial Shows Survival Benefit With Addition of Radiotherapy to Androgen-Deprivation Therapy in Prostate Cancer

In the final prespecified analysis of an Intergroup trial (NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110) reported in the Journal of Clinical Oncology, Mason et al found that overall survival and cancer-specific survival at 8 years were significantly greater with ...

prostate cancer

Genomic Classifier Score Identifies Risk of Metastasis and Benefit of Adjuvant Radiotherapy After Radical Prostatectomy

In a study reported in the Journal of Clinical Oncology, Den et al found that a 22-biomarker genomic classifier score was predictive of a greater risk of metastasis and benefit of adjuvant vs salvage radiotherapy after radical prostatectomy for prostate cancer. Metastasis Risk The study involved...

prostate cancer

Hypofractionated Radiotherapy Not Noninferior to Standard Radiotherapy in Acute Toxicity in Phase III Prostate Cancer Trial

In the Dutch phase III HYPRO trial reported in The Lancet Oncology, Aluwini et al found that hypofractionated radiotherapy was not noninferior to standard fractionated radiotherapy in acute genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer. Efficacy...

prostate cancer

Final Survival Analysis in COU-AA-302 Shows Benefit of Adding Abiraterone to Prednisone in Chemotherapy-Naive Castration-Resistant Prostate Cancer

In the final analysis of overall survival in the COU-AA-302 trial, reported in The Lancet Oncology by Ryan et al, the addition of abiraterone acetate (Zytiga) to prednisone significantly prolonged survival in chemotherapy-naive patients with castration-resistant prostate cancer. Abiraterone had...

prostate cancer

RTOG 9910 Trial Shows No Benefit of Longer Androgen Suppression Before Radiotherapy for Localized Prostate Cancer

As reported by Pisansky et al in the Journal of Clinical Oncology, the Radiation Therapy Oncology Group (RTOG) 9910 trial showed no benefit of extending the duration of pre–radiation therapy androgen suppression on survival or disease control among patients with localized prostate cancer....

prostate cancer

Low Prostate Cancer Mortality in Long-Term Follow-up of Canadian Active Surveillance Cohort

In a study reported in the Journal of Clinical Oncology, Klotz et al found that 1.5% of prostate cancer patients in a Canadian active surveillance cohort died from the disease during up to 16 years of follow-up. Study Details The study involved 993 men with favorable-risk prostate cancer who were ...

prostate cancer

Urinary PCA3 Adds to Predictive Models in Patients Presenting for Initial and Repeat Biopsy for Detection of Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Wei et al found that use of urinary prostate cancer antigen 3 (PCA3) measurement could improve avoidance of repeat prostate biopsy and detection of prostate cancer in biopsy-naive patients. This National Cancer Institute study involved...

prostate cancer

Postdiagnosis Aspirin Use Associated With Reduced Disease-Specific Mortality Only in High-Risk Subgroup of Men With Nonmetastatic Prostate Cancer

A recent analysis of a large clinical database indicated that postdiagnosis aspirin use was associated with a 57% reduction in prostate cancer–specific mortality among men with nonmetastatic prostate cancer. In a study in a prospective cohort reported in the Journal of Clinical Oncology,...

prostate cancer

Greater Suppression of Intraprostatic Androgens by Adding Abiraterone to LHRH Agonist in Patients With Prostate Cancer

In a phase II study reported in the Journal of Clinical Oncology, Taplin et al found that the addition of neoadjuvant abiraterone acetate (Zytiga) to the luteinizing hormone–releasing hormone (LHRH) agonist leuprolide acetate resulted in greater suppression of intraprostatic androgens in...

prostate cancer

ALSYMPCA Subgroup Analysis: Radium-223 Survival Benefit Irrespective of Prior Docetaxel in Castration-Resistant Prostate Cancer With Bone Metastases

The phase III ALSYMPCA trial showed that radium-223 (Xofigo) increased overall survival vs placebo patients with castration-resistant prostate cancer and symptomatic bone metastases.  In a prespecified subgroup analysis reported in The Lancet Oncology, Hoskin et al found that overall survival...

prostate cancer

Adjuvant Radiotherapy Benefits Survival in Subsets of Patients With Node-Positive Prostate Cancer

In an analysis of outcomes in patients with node-positive prostate cancer reported in the Journal of Clinical Oncology, Abdollah et al found that adjuvant radiotherapy is associated with a survival benefit in patients with low-volume nodal disease in the setting of intermediate- to high-grade...

prostate cancer

Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer: Final Analysis of Early-Access Protocol Study

Abiraterone acetate (Zytiga) is approved for use in combination with prednisone in the treatment of metastatic castration-resistant prostate cancer. As reported by Sternberg et al in The Lancet Oncology, results of an open-label, early-access protocol trial initiated prior to approval indicated no...

issues in oncology
prostate cancer

AR-V7 in Circulating Tumor Cells Associated With Resistance to Enzalutamide and Abiraterone in Prostate Cancer

The androgen receptor isoform encoded by splice variant 7 is constitutively active as a transcription factor, despite lacking the ligand-binding domain that is the target of enzalutamide (Xtandi) and abiraterone (Zytiga). In a study reported in The New England Journal of Medicine, Antonarakis et al ...

prostate cancer

Cabozantinib Active in Pretreated Metastatic Castration-Resistant Prostate Cancer

In a phase II expansion study reported in the Journal of Clinical Oncology, Smith et al found that the multikinase inhibitor cabozantinib (Cometriq) showed activity in previously treated metastatic castration-resistant prostate cancer. Cabozantinib targets include VEGFR2 and MET kinases. Study...

prostate cancer

Safe Integration of Surgical Innovations Essential to Patient Safety: Study Evaluates Minimally-Invasive Radical Prostatectomy

In the introduction to a cohort study reported in JAMA Surgery, Parsons et al stated “Surgical innovations disseminate in the absence of coordinated systems to ensure their safe integration into clinical practice, potentially exposing patients to increased risk for medical error.” Their ...

prostate cancer

Male Pattern Baldness at Age 45 May Be Associated With Aggressive Prostate Cancer

In a prospective cohort study in the population of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Zhou et al found that frontal plus moderate vertex baldness at age 45 is associated with increased risk of aggressive prostate cancer. The findings were reported in the...

prostate cancer

Baseline Results of the UK Phase III ProtecT Trial of Active Monitoring, Radical Prostatectomy, or Radiotherapy for Localized Prostate Cancer

The UK phase III ProtecT trial is comparing the effectiveness of active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. Lane et al have provided baseline results of the trial in an article in The Lancet Oncology. Study Details In the trial, men aged 50...

prostate cancer

ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer

The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...

prostate cancer

No Mortality Differences With Intermediate- or Short-Term Androgen Suppression With or Without Zoledronic Acid in Locally Advanced Prostate Cancer

In a phase III Australian/New Zealand trial (TROG 03.04 RADAR) reported in The Lancet Oncology, Denham et al found no differences in prostate cancer–specific or all-cause mortality with intermediate-term androgen suppression and radiotherapy or short-term suppression plus radiotherapy with or ...

prostate cancer
issues in oncology

ERSPC 13-Year Follow-up: Reduction in Prostate Cancer Mortality With PSA Screening, but High Overdiagnosis Rates Remain a Concern, Say Authors

The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...

prostate cancer
issues in oncology

Enzalutamide Increases Time to First Skeletal-Related Event and Improves Quality-of-Life Outcomes in Castration-Resistant Prostate Cancer

In the phase III international AFFIRM trial, enzalutamide (Xtandi) was shown to improve overall survival vs placebo in men with metastatic castration-resistant prostate cancer after progression on docetaxel. In an analysis of secondary endpoints reported in The Lancet Oncology, Fizazi et al found...

solid tumors
prostate cancer

Study Suggests That Primary Androgen-Deprivation Therapy Does Not Improve Long-Term Survival in Older Patients With Localized Prostate Cancer

Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Lu-Yao et al found that primary androgen-deprivation therapy ...

prostate cancer

Depression Associated With Less Definitive Therapy and Poorer Survival in Men With Clinically Localized Prostate Cancer

In a population-based cohort study reported in the Journal of Clinical Oncology, Prasad et al found that men with depressive disorder prior to prostate cancer diagnosis were significantly less likely to undergo definitive therapy and had worse overall survival across all risk strata compared with...

prostate cancer

Minority of Older Patients With Low-Risk Prostate Cancer Managed by Observation

Most older men with low-risk prostate cancer receive upfront treatment, despite absence of clear survival benefit and potential for morbidity. In a retrospective cohort study reported in JAMA Internal Medicine, Hoffman et al found that use of observation as management in this setting varied widely...

prostate cancer

New Androgen Receptor Inhibitor Shows Activity in Metastatic Castration-Resistant Prostate Cancer

ODM-201 is a novel androgen receptor inhibitor—structurally distinct from enzalutamide (Xtandi)—that acts via high-affinity binding to the androgen receptor and inhibition of receptor nuclear translocation. In the phase I/II ARADES trial reported in The Lancet Oncology, Fizazi et al...

solid tumors
prostate cancer

Vasectomy Associated With Modestly Increased Risk of High-Grade and Lethal Prostate Cancer

An analysis of data from the Health Professionals Follow-Up Study reported by Siddiqui et al in the Journal of Clinical Oncology indicates that vasectomy is associated with a modestly but significantly increased risk of high-grade and lethal prostate cancer. The study involved data from 49,405...

prostate cancer

ASCO 2014: Enzalutamide Before Chemotherapy Prolongs Progression-Free and Overall Survival in Metastatic Prostate Cancer

The androgen receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Beer et al found that...

prostate cancer

No Overall Survival Improvement With Ipilimumab After Radiotherapy in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel

In a phase III trial (CA184-043) reported in The Lancet Oncology, Kwon et al assessed the effects of adding ipilimumab (Yervoy) after radiotherapy in patients with metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy. The investigators found no improvement...

prostate cancer

Radium-223 Dichloride Significantly Prolongs Time to First Symptomatic Skeletal Event in Patients With Castration-Resistant Prostate Cancer

In an article in The Lancet Oncology, Sartor et al report symptomatic skeletal event outcomes in the phase III ALSYMPCA trial, which was the study supporting the May 2013 approval of radium-233 dichloride (Xofigo) in patients with castration-resistant prostate cancer and bone metastases. They found ...

prostate cancer
issues in oncology

Tools for Identifying Pathologically Insignificant Prostate Cancer Are Inaccurate In Unscreened Men

In a study reported in British Journal of Cancer, Shaw et al assessed the accuracy of several reported criteria for identifying insignificant prostate cancer for active surveillance in a population of unscreened men. None of the examined tools provided sufficient discrimination of insignificant...

prostate cancer

European Phase II Study Indicates Activity of Enzalutamide in Hormone-Naive Prostate Cancer

As reported in The Lancet Oncology by Tombal et al, a single-arm phase II trial of the androgen receptor inhibitor enzalutamide (Xtandi) has shown that the agent is active in suppressing disease and well tolerated in men with hormone-naive prostate cancer. In this ongoing trial, 67 men with...

prostate cancer

Preclinical Study Suggests Benefits of Increased Tumor Perfusion and Reduced Tumor Hypoxia With Exercise in Prostate Cancer

In a study reported in the Journal of the National Cancer Institute, McCullough et al used an orthotopic rat model of prostate cancer to assess the effects of exercise on tumor hemodynamics and tissue hypoxia. Their findings of enhanced tumor perfusion and diminished tumor hypoxia suggest that...

prostate cancer
issues in oncology

Swedish Study Shows Lower Prostate Cancer Mortality in High-Incidence Areas

In a study reported in the Journal of the National Cancer Institute, Stattin et al found that rates of prostate cancer mortality, excess mortality in men with prostate cancer, and metastatic prostate cancer were lower in counties in Sweden with higher vs lower incidence of prostate cancer that...

issues in oncology
prostate cancer

Circulating Tumor Cell Count and Early Change in Count Are Prognostic for Survival in First-Line Docetaxel Treatment of Prostate Cancer

As reported in the Journal of Clinical Oncology, Goldkorn et al assessed the prognostic value of circulating tumor cell counts in patients with metastatic castration-resistant prostate cancer receiving standard first-line docetaxel plus prednisone with or without atrasentan in the SWOG S0421 trial. ...

prostate cancer

Stereotactic Body Radiation Costs Less but Is Associated With More Genitourinary Toxicity vs Intensity-Modulated Radiation Therapy for Prostate Cancer

In a retrospective Medicare-based study reported in the Journal of Clinical Oncology, Yu et al found that although stereotactic body radiation therapy is associated with lower treatment costs than intensity-modulated radiation therapy in treatment of prostate cancer, it is also associated with...

prostate cancer
myelodysplastic syndromes

No Apparent Increased Risk of Myelodysplastic Syndrome With Definitive Radiotherapy in Prostate Cancer

Exposure to ionizing radiation has been associated with increased risk of myelodysplastic syndrome, and it remains unclear whether radiation doses used in prostate cancer treatment result in increased risk. In a retrospective cohort study reported in the Journal of the National Cancer Institute,...

prostate cancer

Continued Survival Benefits With Radical Prostatectomy in Longer-Term Follow-up in Scandinavian Prostate Cancer Group-4 Trial

As reported in The New England Journal of Medicine by Bill-Axelson et al, additional long-term follow-up in the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) continues to show significant benefits of radical prostatectomy vs watchful waiting in early prostate cancer, including reduced risk of ...

prostate cancer

High Bone Biomarker Levels Linked to Preferential Survival Benefit of Atrasentan in Castration-Resistant Prostate Cancer With Skeletal Metastases

Although elevated markers of bone turnover are associated with poor survival in castration-resistant prostate cancer, the association of these markers with outcome in the setting of bone-targeted therapy is uncertain. In a study reported in the Journal of the National Cancer Institute, Lara et al...

prostate cancer

No Benefit of Early Zoledronic Acid in Reducing Skeletal-Related Events in Castration-Sensitive Prostate Cancer With Bone Metastases

As reported in the Journal of Clinical Oncology by Smith et al, the double-blind phase III Cancer and Leukemia Group B (CALGB) 9020/Alliance trial assessed the effect of early initiation of zoledronic acid in reducing risk of skeletal-related events in men with castration-sensitive prostate cancer. ...

prostate cancer

No Overall Survival Advantage for Escalated-Dose vs Control-Dose Conformal Radiotherapy for Prostate Cancer at 10 Years

As reported in The Lancet Oncology by Dearnaley et al, the 10-year follow-up of the phase III open-label MRC RT01 trial showed continued benefit of escalated-dose vs control-dose conformal radiotherapy in biochemical progression-free survival in patients with prostate cancer but no overall survival ...

solid tumors
prostate cancer

High Incidence of Complications Other Than Urinary Incontinence or Erectile Dysfunction After Prostatectomy or Radiotherapy for Prostate Cancer

Studies of complications of surgery or radiotherapy for prostate cancer generally focus on incontinence and erectile dysfunction. In a population-based cohort study reported in The Lancet Oncology, Nam et al assessed the frequency of other complications associated with such treatment and found high ...

prostate cancer

Higher Dietary Lycopene Intake Associated With Reduced Risk of Lethal Prostate Cancer and Reduced Tumor Angiogenesis

In a study reported in the Journal of the National Cancer Institute, Zu et al found that higher dietary lycopene intake was associated with reduced risk of lethal prostate cancer and reduced tumor angiogenesis. Lycopene-rich foods include tomatoes and tomato-based products. Study Details The...

prostate cancer
issues in oncology

Model of Individualized Estimates Shows Risk of Overdiagnosis in Screening-Detected Prostate Cancers Varies Widely by Age, PSA, and Gleason Score

It is estimated that overdiagnosis occurs in approximately 20% to 40% of prostate cancers detected at screening in U.S. men aged 50 to 84 years, with the likelihood of overdiagnosis varying widely according to patient age and tumor characteristics. In a study reported in the Journal of the...

prostate cancer

No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...

prostate cancer

Prognostic Model Predicts Metastatic Castration-Resistant Prostate Cancer Survival in Second-Line Chemotherapy After Docetaxel

In a study reported in the Journal of the National Cancer Institute, Susan Halabi, MD, of Duke University Medical Center, and colleagues developed and validated a prognostic model predicting prostate cancer survival in patients receiving second-line chemotherapy for castration-resistant...

prostate cancer

Dasatinib Plus Docetaxel Does Not Improve Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Data suggest that Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis and that the Src kinase inhibitor dasatinib (Sprycel) might exhibit synergy with docetaxel in prostate cancer. In a phase III trial (READY) reported in The Lancet Oncology, ...

skin cancer
prostate cancer

Personal History of Prostate Cancer Increases Risk of Melanoma

History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer and recent data suggest that severe teenage acne is a risk factor for melanoma. In a study reported in the Journal of Clinical Oncology, Wen-Qing Li, PhD, of the...

prostate cancer

Statin Use Reduces Cancer-Specific and All-Cause Mortality in Patients With Nonmetastatic Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Oriana Yu, MD, of Jewish General Hospital in Montreal, and colleagues assessed the association of statin use with prostate cancer mortality and all-cause mortality in men with nonmetastatic prostate cancer. They found that postdiagnostic ...

prostate cancer

Problematic Symptoms After Prostate Biopsy Associated With Anxiety

In a study reported in the Journal of Clinical Oncology, Julia Wade, PhD, of Bristol University, United Kingdom, and colleagues assessed the psychological impact of prostate biopsy. They found that postbiopsy symptoms can be associated with increased anxiety, independent of anxiety associated...

prostate cancer

Urologist Ownership of Intensity-Modulated Radiation Therapy Services Significantly Increases Use of Treatment for Prostate Cancer

In a study reported in The New England Journal of Medicine, Jean M. Mitchell, PhD, of Georgetown University, examined patterns of use of intensity-modulated radiation therapy to treat prostate cancer among urologists in private practice who have integrated intensity-modulated radiation therapy into ...

Advertisement

Advertisement



Advertisement